新型体外肝脏代谢模型及其应用进展

卢思翰 ,  鲍广霖 ,  孙建国

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 975 -989.

PDF (682KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 975 -989. DOI: 10.12092/j.issn.1009-2501.2026.07.014
综述与讲座

新型体外肝脏代谢模型及其应用进展

作者信息 +

Novel in vitro liver metabolism models and their applications progress

Author information +
文章历史 +
PDF (698K)

摘要

药物的肝脏代谢研究对药物开发、临床用药指导及药物安全性评估具有重要意义。传统体外肝脏模型虽应用广泛,但在功能维持、预测准确性与生理模拟方面存在局限性,促使多种新型体外肝脏模型被开发。现有综述多侧重于新型模型构建技术的介绍或性能的比较,而系统梳理不同新型模型在药物代谢研究中应用特点的文献较少。在综述近年来新型体外肝脏模型特点及其所采用新技术的基础上,本文进一步将模型功能特性与具体药物代谢研究应用场景对应分析,归纳其在代谢稳定性、代谢物鉴定与药物相互作用评估等方面的表现。以期为体外模型的合理选择与规范化应用提供参考,支持药物的临床前研究与临床应用。

Abstract

Studies of hepatic drug metabolism are crucial for drug development, clinical dosing guidance, and assessment of drug safety. Although traditionalin vitro liver models have been widely used, their limitations in maintaining hepatic function, predictive accuracy, and physiological fidelity have spurred the development of various advanced in vitro liver models. Previous reviews have focused on the technologies used for constructing novel models or on comparative evaluations of their performance, whereas systematic analyses of the application characteristics of different advanced models in drug metabolism research remain limited. Based on a comprehensive review of recent advanced in vitro liver models and the novel technologies they employ, this article further aligns model functional characteristics with specific drug-metabolism research scenarios and summarizes their performance in metabolic stability assessment, metabolite identification, and the evaluation of drug–drug interactions. This review aims to provide guidance for the rational selection and standardized application of in vitro models, thereby supporting preclinical research and clinical use of drugs.

关键词

肝脏 / 生物转化 / 体外研究 / 代谢清除率 / 药物相互作用

Key words

liver / biotransformation / in vitro techniques / metabolic clearance rate / drug interaction

引用本文

引用格式 ▾
卢思翰,鲍广霖,孙建国. 新型体外肝脏代谢模型及其应用进展[J]. 中国临床药理学与治疗学, 2026, 31(7): 975-989 DOI:10.12092/j.issn.1009-2501.2026.07.014

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models[J].J Clin Pharmacol, 2001, 41(11): 1149-1179.

[2]

Almazroo OA, Miah MK, Venkataramanan R.Drug metabolism in the liver[J].Clin Liver Dis, 2017, 21(1): 1-20.

[3]

Zushin PH, Mukherjee S, Wu JC. FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches[J].J Clin Invest, 2023, 133(21): e273567.

[4]

王颖, 潘国宇. 肝样细胞模型在药物肝脏代谢和毒性研究中的进展[J].药学进展, 2018, 42(8): 581-591.

[5]

Li CM, Lu Y, Narayanan R, et al. Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles[J].Drug Metab Dispos, 2010, 38(11): 2032-2039.

[6]

Sowjanya G, Ganapaty S, Sharma R. In vitro test methods for metabolite identification: a review[J].Asian J Pharm Pharmacol, 2019, 5(4): 441-450.

[7]

López-Terrada D, Cheung SW, Finegold MJ, et al. Hep G2 is a hepatoblastoma-derived cell line[J].Hum Pathol, 2009, 40(10): 1512-1515.

[8]

Westerink WM, Schoonen WG.Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells[J].Toxicol In Vitro, 2007, 21(8): 1592-1602.

[9]

Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus[J].Proc Natl Acad Sci U S A, 2002, 99(24): 15655-15660.

[10]

Guillouzo A, Corlu A, Aninat C, et al. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics[J].Chem Biol Interact, 2007, 168(1): 66-73.

[11]

Klein S, Mueller D, Schevchenko V, et al. Long-term maintenance of HepaRG cells in serum-free conditions and application in a repeated dose study[J].J Appl Toxicol, 2014, 34(10): 1078-1086.

[12]

Wilkening S, Stahl F, Bader A.Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties[J].Drug Metab Dispos, 2003, 31(8): 1035-1042.

[13]

Green CJ, Charlton CA, Wang LM, et al. The isolation of primary hepatocytes from human tissue: optimising the use of small non-encapsulated liver resection surplus[J].Cell Tissue Bank, 2017, 18(4): 597-604.

[14]

Keemink J, Oorts M, Annaert P. Primary Hepatocytes in Sandwich Culture[J].Methods Mol Biol, 2015, 1250: 175-188.

[15]

Yang K, Guo C, Woodhead JL, et al. Sandwich-cultured hepatocytes as a tool to study drug disposition and drug-induced liver injury[J].J Pharm Sci, 2016, 105(2): 443-459.

[16]

Nakakariya M, Ono M, Amano N, et al. In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes[J].Drug Metab Dispos, 2012, 40(3): 602-609.

[17]

Bi YA, Kimoto E, Sevidal S, et al. In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation[J].Drug Metab Dispos, 2012, 40(6): 1085-1092.

[18]

Wu YL, Xue YR, Guo ZT, et al. Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes[J].Acta Pharmacol Sin, 2022, 43(3): 747-756.

[19]

Cox CR, Lynch S, Goldring C, et al. Current perspective: 3D spheroid models utilizing human-based cells for investigating metabolism-dependent drug-induced liver injury[J].Front Med Technol, 2020, 2: 611913.

[20]

Fontoura JC, Viezzzer C, Dos Santos FG, et al. Comparison of 2D and 3D cell culture models for cell growth, gene expression and drug resistance[J].Mater Sci Eng C, 2020, 107: 110264.

[21]

Vu B, Souza GR, Dengjel J.Scaffold-free 3D cell culture of primary skin fibroblasts induces profound changes of the matrisome[J].Matrix Biol Plus, 2021, 11: 100066.

[22]

Ho TC, Chang CC, Chan HP, et al. Hydrogels: properties and applications in biomedicine[J].Molecules, 2022, 27(9): 2829.

[23]

Antoine EE, Vlachos PP, Rylander MN.Review of collagen I hydrogels for bioengineered tissue microenvironments: characterization of mechanics, structure, and transport[J].Tissue Eng Part B Rev, 2014, 20(6): 683-696.

[24]

Deng S, Zhu Y, Zhao X, et al. Efficient fabrication of monodisperse hepatocyte spheroids and encapsulation in hybrid hydrogel with controllable extracellular matrix effect[J].Biofabrication, 2021, 14(1): 015009.

[25]

Zhang N, Milleret V, Thompson-Steckel G, et al. Soft hydrogels featuring in-depth surface density gradients for the simple establishment of 3D tissue models for screening applications[J].SLAS Discov, 2017, 22(5): 635-644.

[26]

Lin RZ, Chou LF, Chien CC, et al. Dynamic analysis of hepatoma spheroid formation: roles of E-cadherin and beta1-integrin[J].Cell Tissue Res, 2006, 324(3): 411-422.

[27]

Foty R. A simple hanging drop cell culture protocol for generation of 3D spheroids[J].J Vis Exp, 2011(51): e2720.

[28]

Ryu NE, Lee SH, Park H. Spheroid culture system methods and applications for mesenchymal stem cells[J].Cells, 2019, 8(12): 1532.

[29]

Papapostolou I, Bochen F, Peinelt C, et al. A simple and fast method for the formation and downstream processing of cancer-cell-derived 3D spheroids: an example using nicotine-treated A549 lung cancer 3D spheres[J].Methods Protoc, 2023, 6(5): 92.

[30]

Hurrell T, Ellero AA, Masso ZF, et al. Characterization and reproducibility of HepG2 hanging drop spheroids toxicology in vitro[J].Toxicol In Vitro, 2018, 50: 86-94.

[31]

Ramaiahgari SC, Waidyanatha S, Dixon D, et al. Three-dimensional (3D) HepaRG spheroid model With physiologically relevant xenobiotic metabolism competence and hepatocyte functionality for liver toxicity screening[J].Toxicol Sci, 2017, 160(1): 189-199.

[32]

Shin DS, Seo H, Yang JY, et al. Quantitative evaluation of cytochrome P450 3A4 inhibition and Hepatotoxicity in HepaRG 3-D spheroids[J].Int J Toxicol, 2018, 37(5): 393-403.

[33]

Bell CC, Chouhan B, Andersson LC, et al. Functionality of primary hepatic non-parenchymal cells in a 3D spheroid model and contribution to acetaminophen hepatotoxicity[J].Arch Toxicol, 2020, 94(4): 1251-1253.

[34]

Baze A, Parmentier C, Hendriks DFG, et al. Three-dimensional spheroid primary human hepatocytes in monoculture and coculture with nonparenchymal cells[J].Tissue Eng Part C Methods, 2018, 24(9): 534-545.

[35]

Proctor WR, Foster AJ, Vogt J, et al. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury[J].Arch Toxicol, 2017, 91(8): 2849-2863.

[36]

Kanebratt KP, Janefeldt A, Vilén L, et al. Primary human hepatocyte spheroid model as a 3D In vitro platform for metabolism studies[J].J Pharm Sci, 2021, 110(1): 422-431.

[37]

Huch M, Koo BK. Modeling mouse and human development using organoid cultures[J].Development, 2015, 142(18): 3113-3125.

[38]

Harrison SP, Baumgarten SF, Verma R, et al. Liver organoids: recent developments, limitations and potential[J].Front Med (Lausanne), 2021, 8: 574047.

[39]

Huch M, Dorrell C, Boj SF, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration[J].Nature, 2013, 494(7436): 247-250.

[40]

Huch M, Gehart H, Van Boxtel R, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver[J].Cell, 2015, 160(1-2): 299-312.

[41]

Hu H, Gehart H, Artegiani B, et al. Long-Term expansion of functional mouse and human hepatocytes as 3D organoids[J].Cell, 2018, 175 (6): 1591-1606. e1519.

[42]

Huch M, Boj SF, Clevers H. Lgr5 (+) liver stem cells, hepatic organoids and regenerative medicine[J].Regen Med, 2013, 8(4): 385-387.

[43]

Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening[J].Nat Med, 2017, 23(12): 1424-1435.

[44]

Gong D, Mo J, Zhai M, et al. Advances, challenges and future applications of liver organoids in experimental regenerative medicine[J].Front Med (Lausanne), 2024, 11: 1521851.

[45]

Drost J, Clevers H. Translational applications of adult stem cell-derived organoids[J].Development, 2017, 144(6): 968-975.

[46]

Broutier L, Andersson-Rolf A, Hindley CJ, et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation[J].Nat Protoc, 2016, 11(9): 1724-1743.

[47]

Zhu L, Liu S, Wang Z, et al. Modeling hepatic steatosis with human adult stem cell-derived liver organoids[J].iScience, 2025, 28(5): 112344.

[48]

Nantasanti S, Spee B, Kruitwagen HS, et al. Disease modeling and gene therapy of copper storage disease in canine Hepatic organoids[J].Stem Cell Reports, 2015, 5(5): 895-907.

[49]

Ouchi R, Togo S, Kimura M, et al. Modeling Steatohepatitis in humans with pluripotent stem cell-derived organoids[J].Cell Metab, 2019, 30 (2): 374-384. e376.

[50]

Thompson WL, Takebe T.Generation of multi-cellular human liver organoids from pluripotent stem cells[J].Methods Cell Biol, 2020, 159: 47-68.

[51]

Mun SJ, Hong YH, Shin Y, et al. Efficient and reproducible generation of human induced pluripotent stem cell-derived expandable liver organoids for disease modeling[J].Sci Rep, 2023, 13(1): 22935.

[52]

Harrison SP, Siller R, Tanaka Y, et al. Scalable production of tissue-like vascularized liver organoids from human PSCs[J].Exp Mol Med, 2023, 55(9): 2005-2024.

[53]

An L, Liu Y, Liu Y.Organ-on-a-chip applications in microfluidic platforms[J].Micromachines (Basel), 2025, 16(2): 256.

[54]

Kimura H, Sakai Y, Fujii T. Organ/body-on-a-chip based on microfluidic technology for drug discovery[J].Drug Metab Pharmacokinet, 2018, 33(1): 43-48.

[55]

Docci L, Milani N, Ramp T, et al. Exploration and application of a liver-on-a-chip device in combination with modelling and simulation for quantitative drug metabolism studies[J].Lab Chip, 2022, 22(6): 1187-1205.

[56]

Godoy P, Hewitt NJ, Albrecht U, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME[J].Arch Toxicol, 2013, 87(8): 1315-1530.

[57]

Ma Y, Hu L, Tang J, et al. Three-dimensional cell co-culture liver models and their applications in pharmaceutical research[J].Int J Mol Sci, 2023, 24(7): 6321.

[58]

Caplin JD, Granados NG, James MR, et al. Microfluidic organ-on-a-chip technology for advancement of drug development and toxicology[J].Adv Healthc Mater, 2015, 4(10): 1426-1450.

[59]

Fitzpatrick E, Wu Y, Dhadda P, et al. Coculture with mesenchymal stem cells results in improved viability and function of human hepatocytes[J].Cell Transplant, 2015, 24(1): 73-83.

[60]

Bale SS, Golberg I, Jindal R, et al. Long-term coculture strategies for primary hepatocytes and liver sinusoidal endothelial cells[J].Tissue Eng Part C Methods, 2015, 21(4): 413-422.

[61]

Bale SS, Borenstein JT.Microfluidic cell culture platforms to capture hepatic physiology and complex cellular interactions[J].Drug Metab Dispos, 2018, 46(11): 1638-1646.

[62]

Zhang MY, Lee PJ, Hung PJ, et al. Microfluidic environment for high density hepatocyte culture[J].Biomed Microdevices, 2008, 10(1): 117-121.

[63]

Lopa S, Piraino F, Talò G, et al. Microfluidic biofabrication of 3d multicellular spheroids by modulation of non-geometrical parameters[J].Front Bioeng Biotechnol, 2020, 8: 366.

[64]

Taroncher M, Gonzalez-Suarez AM, Gwon K, et al. Using microfluidic hepatic spheroid cultures to assess liver toxicity of T-2 mycotoxin[J].Cells, 2024, 13(11): 1426.

[65]

Toh YC, Lim TC, Tai D, et al. A microfluidic 3D hepatocyte chip for drug toxicity testing[J].Lab Chip, 2009, 9(14): 2026-2035.

[66]

Bavli D, Prill S, Ezra E, et al. Real-time monitoring of metabolic function in liver-on-chip microdevices tracks the dynamics of mitochondrial dysfunction[J].Proc Natl Acad Sci U S A, 2016, 113(16): E2231-E2240.

[67]

Liu Y, Li H, Yan S, et al. Hepatocyte cocultures with endothelial cells and fibroblasts on micropatterned fibrous mats to promote liver-specific functions and capillary formation capabilities[J].Biomacromolecules, 2014, 15(3): 1044-1054.

[68]

Busche M, Tomilova O, Schütte J, et al. HepaChip-MP - a twenty-four chamber microplate for a continuously perfused liver coculture model[J].Lab Chip, 2020, 20(16): 2911-2926.

[69]

Sung JH.Pharmacokinetic-based multi-organ chip for recapitulating organ interactions[J].Methods Cell Biol, 2018, 146: 183-197.

[70]

Li ZA, Tuan RS.Towards establishing human body-on-a-chip systems[J].Stem Cell Res Ther, 2022, 13(1): 431.

[71]

Milani N, Parrott N, Ortiz Franyuti D, et al. Application of a gut-liver-on-a-chip device and mechanistic modelling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil[J].Lab Chip, 2022, 22(15): 2853-2868.

[72]

Wang M, Sasaki Y, Sakagami R, et al. Perfluoropolyether-based gut-liver-on-a-chip for the evaluation of first-pass metabolism and oral bioavailability of drugs[J].ACS Biomater Sci Eng, 2024, 10(7): 4635-4634.

[73]

Schimek K, Frentzel S, Luettich K, et al. Human multi-organ chip co-culture of bronchial lung culture and liver spheroids for substance exposure studies[J].Sci Rep, 2020, 10(1): 7865.

[74]

Lin N, Zhou X, Geng X, et al. Repeated dose multi-drug testing using a microfluidic chip-based coculture of human liver and kidney proximal tubules equivalents[J].Sci Rep, 2020, 10(1): 8879.

[75]

Bovard D, Sandoz A, Luettich K, et al. A lung/liver-on-a-chip platform for acute and chronic toxicity studies[J].Lab Chip, 2018, 18(24): 3814-3829.

[76]

Ishida S. Organs-on-a-chip: Current applications and consideration points for in vitro ADME-Tox studies[J].Drug Metab Pharmacokinet, 2018, 33(1): 49-54.

[77]

Mak KK, Epemolu O, Pichika MR. The role of DMPK science in improving pharmaceutical research and development efficiency[J].Drug Discov Today, 2022, 27(3): 705-729.

[78]

Wu Y, Pan L, Chen Z, et al. Metabolite identification in the preclinical and clinical phase of drug development[J].Curr Drug Metab, 2021, 22(11): 838-857.

[79]

Chiba M, Ishii Y, Sugiyama Y.Prediction of hepatic clearance in human from in vitro data for successful drug development[J].AAPS J, 2009, 11(2): 262-276.

[80]

刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J].中国临床药理学与治疗学, 2021, 26(8): 889-913.

[81]

Sodhi JK, Benet LZ.Successful and unsuccessful prediction of human hepatic clearance for lead optimization[J].J Med Chem, 2021, 64(7): 3546-3559.

[82]

Stringer R, Nicklin PL, Houston JB. Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance[J].Xenobiotica, 2008, 38(10): 1313-1329.

[83]

Swift B, Pfeifer ND, Brouwer KL.Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity[J].Drug Metab Rev, 2010, 42(3): 446-471.

[84]

Smith CM, Nolan CK, Edwards MA, et al. A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes[J].J Pharm Sci, 2012, 101(10): 3989-4002.

[85]

Preiss LC, Georgi K, Lauschke VM, et al. Comparison of human long-term liver models for clearance prediction of slowly metabolized compounds[J].Drug Metab Dispos, 2024, 52(6): 539-547.

[86]

Kratochwil NA, Meille C, Fowler S, et al. Metabolic profiling of human long-term liver models and hepatic clearance predictions from in vitro data using nonlinear mixed-effects modeling[J].AAPS J, 2017, 19(2): 534-550.

[87]

Sakolish C, Luo YS, Valdiviezo A, et al. Prediction of hepatic drug clearance with a human microfluidic four-cell liver acinus microphysiology system[J].Toxicology, 2021, 463: 152954.

[88]

Bonn B, Svanberg P, Janefeldt A, et al. Determination of human hepatocyte intrinsic clearance for slowly metabolized compounds: comparison of a primary hepatocyte/stromal cell co-culture with plated primary Hepatocytes and HepaRG[J].Drug Metab Dispos, 2016, 44(4): 527-533.

[89]

Backfisch G, Reder-Hilz B, Hoeckels-Messemer J, et al. High-throughput quantitative and qualitative analysis of microsomal incubations by cocktail analysis with an ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometer system[J].Bioanalysis, 2015, 7(6): 671-683.

[90]

Negi CK, Sakolish C, Tsai HH, et al. Comparative analysis of species-specific hepatocyte function and drug effects in a liver microphysiological system physioMimix LC12 and 96-well plates[J].ACS Pharmacol Transl Sci, 2025.

[91]

Bell CC, Dankers ACA, Lauschke VM, et al. Comparison of Hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study[J].Toxicol Sci, 2018, 162(2): 655-666.

[92]

Ohkura T, Ohta K, Nagao T, et al. Evaluation of human hepatocytes cultured by three-dimensional spheroid systems for drug metabolism[J].Drug Metab Pharmacokinet, 2014, 29(5): 373-378.

[93]

Ramaiahgari SC, Waidyanatha S, Dixon D, et al. From the cover: three-dimensional (3D) HepaRG spheroid model with physiologically relevant xenobiotic metabolism competence and hepatocyte functionality for liver toxicity screening[J].Toxicol Sci, 2017, 159(1): 124-136.

[94]

U. S. Food and Drug Administration.Guidance for Industry; In vitro drug interaction studies - Cytochrome P450 enzyme and transporter mediated drug interactions[EB/OL].2020[2025-10-20].https://www.fda.gov/media/134582/download.

[95]

Fujita Y, Miyake T, Shao X, et al. Omeprazole induces CYP3A4 mRNA expression but not CYP3A4 protein expression in HepaRG cells[J].Biol Pharm Bull, 2024, 47(6): 1218-1223.

[96]

Obach RS, Walsky RL, Venkatakrishnan K, et al. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions[J].J Pharmacol Exp Ther, 2006, 316(1): 336-348.

[97]

Kaur I, Vasudevan A, Rawal P, et al. Primary hepatocyte isolation and cultures: technical aspects, challenges and advancements[J].Bioengineering (Basel), 2023, 10(2): 245.

[98]

Wegler C, Matsson P, Krogstad V, et al. Influence of proteome profiles and intracellular drug exposure on differences in CYP activity in donor-matched human liver microsomes and hepatocytes[J].Mol Pharm, 2021, 18(4): 1792-1805.

[99]

Sison-Young RL, Mitsa D, Jenkins RE, et al. Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication[J].Toxicol Sci, 2015, 147(2): 412-424.

[100]

Järvinen E, Hammer HS, Pötz O, et al. 3D spheroid primary human hepatocytes for prediction of cytochrome P450 and drug transporter induction[J].Clin Pharmacol Ther, 2023, 113(6): 1284-1294.

[101]

Ohri S, Parekh P, Nichols L, et al. Utilization of a human Liver tissue chip for drug-metabolizing enzyme induction studies of perpetrator and victim drugs[J].Drug Metab Dispos, 2025, 53(1): 100004.

[102]

Zhang Z, Farooq M, Prasad B, et al. Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes[J].Drug Metab Dispos, 2015, 43(6): 836-842.

[103]

Pfeifer ND, Goss SL, Swift B, et al. Effect of Ritonavir on (99m) technetium-mebrofenin disposition in humans: A semi-pbpk modeling and in vitro approach to predict transporter-mediated DDIs[J].CPT Pharmacometrics Syst Pharmacol, 2013, 2(1): e20.

[104]

Fukuda H, Nakanishi T, Tamai I.More relevant prediction for in vivo drug interaction of candesartan cilexetil on hepatic bile acid transporter BSEP using sandwich-cultured hepatocytes[J].Drug Metab Pharmacokinet, 2014, 29(1): 94-96.

[105]

Murayama N, Yamazaki H.Cytochrome P450-dependent drug oxidation activities in commercially available hepatocytes derived from human induced pluripotent stem cells cultured for 3 weeks[J].J Toxicol Sci, 2018, 43(4): 241-245.

[106]

Takayama K, Morisaki Y, Kuno S, et al. Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes[J].Proc Natl Acad Sci U S A, 2014, 111(47): 16772-16777.

[107]

Lee-Montiel FT, Laemmle A, Charwat V, et al. Integrated isogenic human induced pluripotent stem cell-based liver and heart microphysiological systems predict unsafe drug-drug interaction[J].Front Pharmacol, 2021, 12: 667010.

[108]

Skottvoll FS, Hansen FA, Harrison S, et al. Electromembrane extraction and mass spectrometry for liver organoid drug metabolism studies[J].Anal Chem, 2021, 93(7): 3576-3585.

[109]

Ott LM, Ramachandran K, Stehno-Bittel L. An automated multiplexed hepatotoxicity and CYP induction assay using heparg cells in 2D and 3D[J].SLAS Discov, 2017, 22(5): 614-625.

[110]

孙广晨, 李宏宇, 陈江, 等. 类器官在生物医学中研究进展及应用[J].临床军医杂志, 2023, 51(11): 1206-1210.

基金资助

中国医学科学院医学与健康科技创新工程项目(2021-I2M-5-011)

AI Summary AI Mindmap
PDF (682KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉